Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide and Oral Contraceptive PK Interaction
NCT02845219Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2016
- Primary completion
- Dec 2016
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoints: Area under the ethinylestradiol plasma concentration-time curve at Day 82 and Area under the levonorgestrel plasma concentration-time curve at Day 82. Started Jul 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02845219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02845219.